Comparison of Visual Acuity Performed in Office Versus In Residence

NCT ID: NCT05250986

Last Updated: 2022-02-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

325 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-02-14

Study Completion Date

2022-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

GoCheck has developed and deployed a home-based visual acuity test that may be used in-office or in residence. The test methodology utilizes modified ATS and ETDRS protocols with Sloan optotypes, crowding bars and sophisticated algorithms. The objective of this study is to determine if the results of the GoCheck visual acuity test performed in an office setting correlate to the same testing when implemented in the residence

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To address the increasing needs for remote patient assessment, GoCheck has developed and deployed a home-based visual acuity test that may be used in-office or in residence, to meet the changing needs of providers visit time allocation, as well as presenting a standardized form of visual acuity centered around clinically-validated approaches.

The test methodology utilizes modified ETDRS design features with HOTV or Sloan optotypes (based on age), crowding bars, and displays 3 optotypes at a time (arranged vertically) to accommodate smaller screen sizes, but still significantly shortens testing time as opposed to displaying only a single optotype at a time.

The application may be used to screen children old enough to comprehend the test, typically around age 4 through adulthood, during their primary care, or school-based visits, and now, in the home. The purpose of home vision testing is to provide actionable insights into the status of an individual's vision without the need for an in-office visit. The testing results will be able to used by the physician to help determine if additional interventions are necessary.

The objective of this study is to determine if the results of the GoCheck visual acuity test performed in an office setting correlate to the same testing when implemented in the residence.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Refractive Errors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GoCheck Kids (iOS)

Visual Acuity method is used to measure of the sharpness or clearness of vision.

Device: GoCheck Visual Acuity in Office (Windows) Photorefraction method is used to screen amblyopia risk factors.

Intervention Type DEVICE

GoCheck Kids (Windows)

Visual Acuity method is used to measure of the sharpness or clearness of vision.

Intervention Type DEVICE

GoCheck at Home (iOS)

Visual Acuity method is used to measure of the sharpness or clearness of vision.

Intervention Type DEVICE

GoCheck at Home (Windows)

Visual Acuity method is used to measure of the sharpness or clearness of vision.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Ages four (4) to twenty(20) years, inclusive
2. Corrected visual acuity range of 20/16 to 20/100
3. Manifest or cycloplegic refraction within prior six (6) months
4. Ability to comprehend and complete the VA test with age appropriate optotypes

Exclusion Criteria

1. No access to smartphone
2. Inability to read, write, and/or understand English
3. Inability to provide written informed consent or have consent conferred on patient's behalf
4. Subjects from populations otherwise deemed ineligible/unable to provide informed consent and/or participate in studies (detention, correction, rehabilitation, psychiatric residents, etc.)
5. Current pregnancy
6. Any ocular pathology defect(s) except amblyopia, strabismus or refractive error or history of nystagmus.
Minimum Eligible Age

4 Years

Maximum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Gobiquity Mobile Health

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David Huang, MD

Role: STUDY_CHAIR

Oregon Health and Science University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alaska Children's Eye & Strabismus

Anchorage, Alaska, United States

Site Status RECRUITING

Yale School of Medicine, Yale University

New Haven, Connecticut, United States

Site Status NOT_YET_RECRUITING

Medical University of South Carolina-Storm Eye Institute

Charleston, South Carolina, United States

Site Status NOT_YET_RECRUITING

Stern Hospital

Haifa, Tel Aviv, Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Lindsey Sangillo

Role: CONTACT

18605140084

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Robert Arnold, MD

Role: primary

Jill Rotruck, MD

Role: primary

Mae Peterseim, MD

Role: primary

Tamara Wygnanski-Jaffe, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Control of Myopia Using Novel Spectacle Lens Designs
NCT03623074 ACTIVE_NOT_RECRUITING NA